The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II study of best available fluoropyrimidine compared with continuation of gemcitabine (Gem) monotherapy in patients with Gem-refractory pancreatic cancer.
Tatsuya Ioka
Honoraria - Chugai Pharma; Lilly; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Chugai Pharma; Yakult Honsha
Kazuhiro Katayama
No relevant relationships to disclose
Nobuko Ishida
No relevant relationships to disclose
Ryoji Takada
No relevant relationships to disclose
Takuo Yamai
No relevant relationships to disclose
Nobuyasu Fukutake
No relevant relationships to disclose
Reiko Ashida
No relevant relationships to disclose
Hiroyuki Uehara
No relevant relationships to disclose
Hiroaki Ohigashi
No relevant relationships to disclose
Hidenori Takahashi
No relevant relationships to disclose
Osamu Ishikawa
No relevant relationships to disclose